The Status Quo and Countermeasures of “4+7”
Quantity Purchase in China

亚洲社会药学 ›› 2020, Vol. 15 ›› Issue (2): 89-96.

The Status Quo and Countermeasures of “4+7” Quantity Purchase in China

Zhou Yusheng, Wei Xingchen, Piao Huiling, Wang Nan, Wang Xing, Dong Li*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

出版日期:2020-06-20 发布日期:2020-06-19

The Status Quo and Countermeasures of “4+7” Quantity Purchase in China

Zhou Yusheng, Wei Xingchen, Piao Huiling, Wang Nan, Wang Xing, Dong Li*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

Online:2020-06-20 Published:2020-06-19
Contact: Dong Li, associate professor. Major research area: pharmaceutical intellectual property, pharmaceutical international trade research. Tel: 024-23986543, E-mail: sydongli@163.com. E-mail:sydongli@163.com

摘要/Abstract

摘要： Objective To understand the effectiveness and problems of centralized drug procurement in China by analyzing the implementation of the “4+7” pilot work for centralized drug procurement in China. Methods The current situation and existing problems of drug procurement in China were analyzed through the literature research method. Results and Conclusion At present, good social benefits have been achieved for China’s drug procurement through pilot projects in several cities, but there are some serious problems. The proposed countermeasures will help to improve the procurement of pharmaceuticals in China.

关键词: quantity procurement, 4+7, drug bidding

Abstract: Objective To understand the effectiveness and problems of centralized drug procurement in China by analyzing the implementation of the “4+7” pilot work for centralized drug procurement in China. Methods The current situation and existing problems of drug procurement in China were analyzed through the literature research method. Results and Conclusion At present, good social benefits have been achieved for China’s drug procurement through pilot projects in several cities, but there are some serious problems. The proposed countermeasures will help to improve the procurement of pharmaceuticals in China.

Key words: quantity procurement, 4+7, drug bidding

Zhou Yusheng, Wei Xingchen, Piao Huiling, Wang Nan, Wang Xing, Dong Li. The Status Quo and Countermeasures of “4+7” Quantity Purchase in China[J]. 亚洲社会药学, 2020, 15(2): 89-96.

Zhou Yusheng, Wei Xingchen, Piao Huiling, Wang Nan, Wang Xing, Dong Li. The Status Quo and Countermeasures of “4+7” Quantity Purchase in China[J]. Asian Journal of Social Pharmacy, 2020, 15(2): 89-96.

[1]	Piao Huiling, Wei Xingchen, Wang Nan, Wang Xing, Zhou Yusheng, Dong Li. Current Effect of “4+7” Drug Centralized Volume Procurement and Suggestions for Future Improvement [J]. 亚洲社会药学, 2020, 15(4): 198-212.
[2]	Zheng Yongxia, Yang Yue. Discussion on Drug Procurement with Target Quantity in China and Its Problem[J]. 亚洲社会药学, 2019, 14(2): 59-65.

亚洲社会药学

The Status Quo and Countermeasures of “4+7” Quantity Purchase in China

The Status Quo and Countermeasures of “4+7” Quantity Purchase in China

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价